Among others, mutation of the genes encoding the Kirsten rat sarcoma viral oncogene homologue (KRAS) and the V-raf murine sarcoma viral oncogene homolog B1 (BRAF) wes established as two of these mechanisms and preselection of CRC patients with a KRASwt genotype have been shown to increase the therapeutic efficacy of anti-EGFR therapy [7, 8]. This evidence concerns the gene BRAF and colorectal carcinoma.